(Bloomberg) -- Eli Lilly & Co. agreed to buy U.S. biopharma company Morphic Holding Inc. for about $3.2 billion to gain experimental therapies for inflammatory bowel disease and other chronic illnesses.

Most Read from Bloomberg

Biden Narrows Gap With Trump in Swing States Despite Debate Loss Hedge Funds That Piled Into Big Tesla Short Stung by Rally Boeing to Plead Guilty to Fraud for Violating Deal Over 737 Max Crashes French Left Set for Shock Victory Over Macron and Le Pen

Lilly will pay $57 a share for Waltham, Massachusetts-based Morphic, or 79% more than the closing price Friday, the companies said in a statement Monday. Morphic’s board recommends that stockholders tender their shares in the offer.

Morphic is developing a so-called selective oral small molecule inhibitor for the treatment of inflammatory bowel disease. The experimental therapy is currently being evaluated in two mid-stage studies in ulcerative colitis, and an early-stage trial in Crohn’s disease.

Most Read from Bloomberg Businessweek

A World-First Psychedelics Experiment Is Unfolding in Australia How Stocks Became the Game That Record Numbers of Americans Are Playing Dragons and Sex Are Now a $610 Million Business Sweeping Publishing The Rich Investor Club Is Getting Crowded Online Shopping Warehouses Are Reshaping Rural America

©2024 Bloomberg L.P.